Molecular mechanisms of action of stimulant novel psychoactive substances that target the high-affinity transporter for dopamine.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical, computational, and mechanistic literature
PubMed 34888062 · doi:10.1042/NS20210006
What was done
This narrative review synthesized literature on the molecular mechanisms by which stimulant novel psychoactive substances (NPS), such as benzofurans, cathinones, and piperidine derivatives, interact with the dopamine transporter (DAT). The authors evaluated methodologies across in vitro, in vivo, and in silico approaches, focusing particularly on molecular dynamics simulations.
What was found
The abstract reports no quantitative values or statistical metrics. It describes qualitatively that stimulant NPS share the dopamine transporter as a primary biological target to elevate dopamine availability in reward pathways, and that computational modeling helps delineate the structural determinants of their addictive potential.
Why it matters
Understanding the structural and molecular interactions between emerging designer stimulants and the dopamine transporter helps clarify the pharmacological mechanisms driving their addictive liability and health risks.
Limits
This is a narrative review reporting no new human clinical data or quantitative effect estimates. Findings are derived from preclinical, computational, and laboratory models, which do not directly capture human pharmacokinetic variability, behavioral outcomes, or clinical toxicity.